Results 81 to 90 of about 1,588,451 (244)
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. [PDF]
Immunomodulatory therapies, targeting the immune checkpoint receptor-ligand complex PD-1/PD-L1 have shown promising results in early phase clinical trials in solid malignancies, including carcinomas of the head and neck.
Pfarr, Nicole +30 more
core +2 more sources
ABSTRACT Objective The prognosis of glioblastoma (GBM) remains highly unfavorable, largely due to high tumor heterogeneity and an immunosuppressive microenvironment. However, the functional role of PANoptosis in this context is poorly understood. Methods Patients were stratified via K‐means clustering. A risk score model was constructed using prognosis‐
Langfei Tian +6 more
wiley +1 more source
Additional file 6: Figure S4. Immunofluorescent double staining of PD-L1 and CD20 in AITL: PD-L1 (Alexa Fluor-488, green), CD20 (Cy3, red). Nuclei counterstained with DAPI (blue channel).
Markus Tiemann (8545260) +3 more
core +1 more source
Nano‐sized orthopedic implant‐derived particles interact with sensory neurons, with poly(methyl methacrylate) (PMMA)‐associated signal detected in neuronal somata following selective axonal exposure in compartmentalized microfluidic cultures. Label‐free confocal Raman microscopy provides complementary chemical evidence of PMMA‐associated material in ...
Marina Couto +6 more
wiley +1 more source
Summary: The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (PD-L1) on antigen-presenting cells (APCs), is a major mechanism of tumor immune evasion.
Yunlong Zhao +5 more
doaj +1 more source
Ion‐Reconfigurable “N”‐Shaped Antiambipolar Behavior in Organic Electrochemical Transistors
A unique N‐shaped negative differential transconductance (NDT) characteristics is demonstrated in single‐polymer organic electrochemical transistors through a sequential doping–redox–doping process driven by iodide ions. This redox‐driven mechanism enables low‐voltage, ion‐controlled reconfigurability and tunable current modulation, allowing seamless ...
Debdatta Panigrahi +11 more
wiley +1 more source
Background The PD-L1/PD-1 pathway is crucial for immune regulation and has become a target in cancer immunotherapy. However, in order to improve patient selection for immune checkpoint blockade (ICB) therapies, better selection criteria are needed.
Bar Kaufman +13 more
doaj +1 more source
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin +20 more
wiley +1 more source
Background: Programmed death ligand (PD-L1) binds to its receptor PD-1 on T-cells and inhibits the immune response of T-lymphocytes. Cancer cells evade immune surveillance by upregulating PD-L1 expression, leading to tumor progression.
Md Ashab Anwer +5 more
doaj +1 more source
Summary results for patients in the PD-L1-high model.
Summary results for patients in the PD-L1-high model.
Juan Wisnivesky (8374794) +6 more
core +1 more source

